A double‐blind, randomized, vehicle‐controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIRTM) in the management of atopic dermatitis in paediatric patients
- 20 October 2008
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 19 (7), 619-625
- https://doi.org/10.1111/j.1399-3038.2008.00724.x
Abstract
A multicenter, randomized, double-blind, vehicle-controlled clinical study was conducted to evaluate the efficacy and safety of MAS063DP in 60 paediatric patients affected by atopic dermatitis (AD), aged between 2 and 17 years. Using the Investigator's Global Assessment (IGA) score for AD, patients with a score of 2 (mild) or 3 (moderate) were enrolled in the study. Patients were randomly selected to receive MAS063DP (20 patients), MAS060 (20 patients, a similar formulation with lower key ingredients' concentration and no preservatives) or vehicle (20 patients).The study consisted in a treatment period of 43 days, with clinical evaluations at baseline (day 1), days 8, 15, 22, 29 and 43, at which time the treatment was stopped. MAS063DP showed nearly 80% improvement in IGA score at day 22, compared with 16.6% and 26.3% with the MAS060 and vehicle respectively. A statistically significant difference was found by comparing MAS063DP with MAS060 (p < 0.0001); a similar result was evidenced comparing MAS063DP and vehicle (p = 0.001). By contrast, no significant difference was found between MAS060 and vehicle. A statistically significant difference was sustained until the end of the study. MAS063DP may therefore be considered as one of the available regimens effective in the treatment of mild-to-moderate AD in children and adolescents.Keywords
This publication has 11 references indexed in Scilit:
- Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus ReportJournal of Allergy and Clinical Immunology, 2006
- The use of topical calcineurin inhibitors in dermatology: Safety concerns: Report of the American Academy of Dermatology Association Task ForceJournal of the American Academy of Dermatology, 2006
- Efficacy of a Topical Agent, MAS063D (‘Atopiclair’), in the Treatment of Sodium Lauryl Sulphate-Induced Irritant Contact DermatitisExogenous Dermatology, 2003
- Efficacy Evaluation of an Oil-in-Water Emulsion (Dermoflan) in Atopic DermatitisPublished by Medical Journals Sweden AB ,2002
- Atopic dermatitis in infancy and childhood: an ongoing challengePediatric Allergy and Immunology, 2001
- Sparing Effect of Procyanidins fromVitis viniferaon Vitamin E:In vitroStudiesPlanta Medica, 1998
- HYALURONIC ACID AND SKIN: WOUND HEALING AND AGINGInternational Journal of Dermatology, 1996
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Comparative studies of the stereoisomers of glycyrrhetinic acid on anti-inflammatory activities.Journal of Pharmacobio-Dynamics, 1984
- THE ANTI-INFLAMMATORY ACTIVITY OF GLYCYRRHETINIC ACID AND DERIVATIVESJournal of Pharmacy and Pharmacology, 1958